Studies related to Nasal Congestion and Pelargonium sidoides

The Efficacy Of Pelargonium Sidoides In The Treatment Of Upper Respiratory Tract Infections In Children With Transient Hypogammaglobulinemia Of Infancy

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 28
Gender Both Genders
Age Range 1-6
Body Types Average
Notes for this study:
In children with upper respiratory tract infections associated with transient hypogammaglobulinemia of infancy, supplementation of 1.5mL (10 drops) of EPs-7630 thrice daily for a week was able to significantly benefit nasal congestion (71.4% of treatment having no congestion relative to 21.5% of placebo) and appetite. Fever, cough, well being, and myalgia were not affected.

Treatment Of Acute Rhinosinusitis With The Preparation From Pelargonium Sidoides EPs 7630: A Randomized, Double-blind, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 203
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
Supplementation of 60 drops of EPs7630 thrice daily (double the normal dose) in persons with acute rhinosinusitis (of probably bacterial origin) for one week was associated with significantly reduced symptoms and nasal congestion relative to placebo.

Efficacy Of A Pelargonium Sidoides Preparation In Patients With The Common Cold: A Randomized, Double Blind, Placebo-controlled Clinical Trial

Effect Decrease
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 103
Gender Both Genders
Age Range 18-29, 30-44
Body Types Average
Notes for this study:
In adults with cold symptoms for 24-48 hours, supplementation of EPs7630 at 30 drops (1.5mL) thrice daily for up to 10 days and assessed by total symptoms and cold intensity rating scales noted that supplementation was assocatiated with twice the reduction in symptoms than was placebo, and after 10 days 78.8% of persons given the supplement were seen as clinically cured (relative to 31.4% of placebo).

Can The Pelargonium Sidoides Root Extract EPs® 7630 Prevent Asthma Attacks During Viral Infections Of The Upper Respiratory Tract In Children

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 61
Gender Both Genders
Age Range 1-6, 7-12
Notes for this study:
In asthmatic children with viral URTIs, supplementation of the standard doses of EPs7630 was able to reduce nasal congestion and cough but not fever nor muscle aches. There was a significant reduction in asthmatic attacks in the sick group treated with EPs7630 relative to placebo.